DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-179/SLR-015

Timothy Belt
Principle Associate, Regulatory Affairs
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142

Dear Mr. Belt:

Please refer to your supplemental new drug application dated January 21, 2005, received January 25, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Renagel® (sevelamer hydrochloride) 400 & 800 mg Tablets.

This "Changes Being Effected in 30 days" supplemental new drug application provides for the following revisions to the labeling:

1. Under **Precautions, Drug interactions**, section, the following text was added to become the second paragraph:

   Ciprofloxacin: In a study of 15 healthy subjects, a co-administered single dose of 7 Renagel Capsules (approximately 2.8g) decreased the bioavailability of ciprofloxacin by approximately 50%.

2. Under the **Dosage and Administration** section, the following text was added to the second to the last paragraph:

   However, the bioavailability of ciprofloxacin was decreased by approximately 50% when co-administered with Renagel or calcium acetate, in a single dose study.

In addition, we note the following changes:

1. References to Renagel® Capsules (sevelamer hydrochloride) 403 mg were taken out of the label.

2. The name of the drug is not at the top of the last column of the label.

3. Under **Precautions, Drug interactions**, section, the following text, first sentence of the last paragraph:

   However, when administering any other oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on safety or efficacy, the drug should be administered at least one hour before or three hours after Renagel, or the physician should consider monitoring blood levels of the drug.

   was revised to read:

> Furthermore, when administering an oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, the drug should be administered at least one hour before or three hours after Renagel, or the physician should consider monitoring blood levels of the drug.

4. Under the **Adverse Reactions** section, last paragraph, the word "longterm" now reads "long-term".

5. Under the **Dosage and Administration** section, the following text, "any other" was deleted and the word, "its" was added to read,

> When administering an oral drug for which alteration in blood levels could have a clinically significant effect on its safety or efficacy, the drug should be administered at least one hour before or three hours after Renagel, or the physician should consider monitoring blood levels of the drug.

6. The copyright text was deleted:

4712
030204R01
Issued 3/04

and replaced with:

4712
12604R01
Issued 10/04

We have completed our review of this supplemental new drug application. It is approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on January 21, 2005.

If you intend to market NDA 20-926 Renagel® (sevelamer hydrochloride) Capsules, you are required to submit a supplemental new drug application providing for inclusion the capsule labeling of the same information regarding ciprofloxacin.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please call:

Ms. Dianne Paraoan
Regulatory Health Project Manager
(301) 594-5308

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Acting Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Norman Stockbridge

7/25/05 08:56:53 AM